

PCL Department Publications (2011)

Arnot M

Hui K, **Arnot M.I**, Shin HS, Sun HS, and Feng ZP. Functional channel expression of voltage-gated calcium channels in Neonatal Rat Myocytes following Chronic PKA Modulation. *Channels* 5(4): 357-366. 2011.

Brands B

Stoduto G, Mann RE, Ialomiteanu A, Wickens CM, **Brands B**. Examining the link between collision involvement and cocaine use. *Drug Alcohol Depend.* 2011 Nov 7. [Epub ahead of print]

Brands, B, Corea, L, Strike, C, Singh, VAS, Behrooz, R and Rush, B. Demand for substance abuse treatment related to use of crystal methamphetamine in Ontario: an observational study. *Int J Ment Health Addiction* DOI 10.1007/s11 469-011-9362-1 (Published online Dec 3, 2011)

Chirgadze N

Khan S, Mian HS, Sandercock LE, **Chirgadze NY** and Pai EF. Crystal Structure of the Passenger Domain of the Escherichia coli Autotransporter EspP. *J Mol Biol.* 11; 413(5):985-1000, 2011.

Clarke TE, Romanov V, Yuri N. Chirgadze YN, Klomsiri C, Kisselman G, Wu-Brown J, Poole LB, Pai EF, and **Chirgadze NY**. Crystal structure of alkyl hydroperoxidase D like protein PA0269 from *Pseudomonas aeruginosa*: Homology of the AhpD-like structural family. *BMC Structural Biology*, 11:27, 2011.

Kisselman G, Qiu W, Romanov V, Thompson CM, Lam R, Battaile K, Pai EF, **Nickolay Y. Chirgadze**. X-CHIP: An Integrated Platform for High-Throughput Protein Crystallization and On-the-Chip X-Ray Diffraction Data Collection. *Acta Cryst.*, D67, 533-539, 2011.

Clarke TE, Romanov V, Lam R, Gothe SA, Pedd SR, Razumova EB, Lipman RSA, Branstrom AA and **Nickolay Y. Chirgadze**. Structure of *Francisella tularensis* peptidyl-tRNA hydrolase. *Acta Cryst.*, F67, 446–449 47, 2011.

Liao JCC, Lam R, Brazda V, Duan S, Ravichandran M, Ma J, Xiao T, Tempel W, Zuo X, Yun-Xing Wang, **Chirgadze NY** and Arrowsmith CH. Interferon-Inducible Protein 16: Insight into the Interaction with Tumor Suppressor p53. *Structure*, Volume 19, Issue 3, 418-429, 2011.

Dorian P (30)

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaç E, Di Pasquale G, Diaz R, **Dorian P**, et al. the PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. *N Engl J Med.*; 365(24):2268-76, 2011.

Bohm A, Kiss R, **Dorian P**, Pinter A. Complications of variant angina: a case report. *Can J Cardiol.* 2011 Dec 15 [Epub ahead of print].

Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Käåb S, Schotten U, Wegscheider K, Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, **Dorian P**, et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options . Executive summary of the report from the 3rd AFNET/EHRA consensus conference. *Thromb Haemost.*; 106(6):1012-9, 2011.

Farid T, Nair K, Masse S, Azam MA, Maguy A, Lai PF, Umaphathy K, **Dorian P**, et al. Role of KATP channels in the maintenance of ventricular fibrillation in cardiomyopathic human hearts. *Circ Res.*; 109(11):1309-18, 2011.

Thibault B, Harel F, Ducharme A, White M, Frasura-Smith N, Roy D, Philippon F, **Dorian P**, et al. Evaluation of resynchronization therapy for heart failure in patients with a QRS duration greater than 120 ms (GREATER-EARTH) trial: Rationale, design, and baseline characteristics. *Can J Cardiol.*; 27(6):779-86, 2011.

Aufderheide TP, Nichol G, Rea TD, Brown SP, Leroux BG, Pepe PE, Kudenchuk PJ, Christenson J, Daya MR, **Dorian P**, et al. and the Resuscitation Outcomes Consortium (ROC) Investigators. A trial of an impedance threshold device in out-of-hospital cardiac arrest. *N Engl J Med.*; 365(9):798-806, 2011.

Gladstone DJ, Earl KM, Bungard TJ, Cox JL, Bell A, **Dorian P**, et al. New anticoagulants for atrial fibrillation: The beginning of a new era in stroke prevention. *Can J Neurol Sci.*; 38(5):777-82, 2011.

Afatmirni E, Nanthakumar K, Masse S, Nair K, Farid T, Krishnan S, **Dorian P**, Umaphathy K. Predicting refrillation from pre-shock waveforms in optimizing cardiac resuscitation. *Conf Proc IEEE Eng Med Biol Soc.*; 251-4, 2011.

Bigham BL, Koprowicz K, Rea T, **Dorian P**, et al. and the ROC Investigators. Cardiac arrest survival did not increase in the resuscitation outcomes consortium after implementation of the 2005 AHA CPR and ECC guidelines. *Resuscitation.*; 82(8):979-83, 2011.

Ramadeen A, **Dorian P**. Omega-3 polyunsaturated fatty acids: food or medicine? *Heart.*; 97(13):1032-3, 2011.

Dorian P, Ha AC. Does better rate control improve quality of life? Be still my beating heart. *J Am Coll Cardiol.*; 58(17):1804-6, 2011.

Dorian P. Show me the money: The cost of atrial fibrillation. *Can J Cardiol.*; 27(4):401-3, 2011.

Golovchiner G, **Dorian P**, Mangat I, et al. Electrogram-based optimal atrioventricular and interventricular delays of cardiac resynchronization change individually during exercise. *Can J Cardiol.*; 27(3):351-7, 2011.

Jeejeebhoy FM, Zelop CM, Windrim R, Carvalho J, **Dorian P**, Morrison LJ. Management of cardiac arrest in pregnancy: A systematic review. *Resuscitation.*; 82(7):801-9, 2011.

Umopathy K, Foomany FH, **Dorian P**, et al. Real time electrogram analysis for monitoring coronary blood flow during human ventricular fibrillation: Implications for CPR. *Heart Rhythm.*; 8(5):740-9, 2011.

Irvine J, Firestone J, Ong L, Cribbie R, **Dorian P**, et al. A randomized controlled trial of cognitive behavior therapy tailored to psychological adaptation to an implantable cardioverter defibrillator. *Psychosom Med.*; 73(3):226-33, 2011.

Krahn AD, Lee DS, Birnie DS, Healey JS, Crystal E, **Dorian P**, et al. Predictors of short-term complications after implantable cardioverter-defibrillator replacement: Results from the Ontario ICD database. *Circ Arrhythm Electrophysiol.*; 4(2):136-42, 2011.

Pinter A, Sklar L, **Dorian P**. Factitious ventricular tachyarrhythmia outbreak. *Arch Intern Med.*;171(3):191-3, 2011.

Healey JS, Parkash R, Pollak T, Tsang T, **Dorian P**, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: etiology and initial investigations. *Can J Cardiol.* 2011 Feb;27(1):31-7.

Gillis AM, Verma A, Talajic M, Nattel S, **Dorian P**, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. *Can J Cardiol.*; 27(1):47-59, 2011.

Endrenyi L

Chow SC, **Endrenyi L**, Lachenbruch PA, Yang ly, and Chi E. Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics. *Biosimilars*, 1: 13-26, 2011.

Kondra PM, **Endrenyi L**, and Tothfalusi L. The need for additional metrics to assess therapeutic equivalence of some multiphasic modified-release products. *Clin. Therap.* 33: 1214-1219, 2011.

Tothfalusi L and **Endrenyi L**. Sample sizes for designing bioequivalence studies for highly variable drugs. *J. Pharm. Pharmaceut. Sci.* 15: 73-84, 2011.

Chow SC, **Endrenyi L**, Chi E, Yang LY, and Tothfalusi L. Statistical issues in bioavailability/bioequivalence studies. *J. Bioequiv. Bioavail. Suppl.*1-007: 1-8, 2011.

Finkelstein Y

Elzagallaai A, Garcia-Bournissen F, **Finkelstein F**, Bend J, Rieder M, Koren G. Severe bullous hypersensitivity reactions after exposure to carbamazepine in a Han Chinese child with a positive HLA-B*1502 and a negative lymphocyte toxicity assay: Evidence for different pathophysiological mechanisms. *J Pop Therap Clin Pharmacol.* Jan 18(1):e1-e9, 2011.

Finkelstein Y, Soon G, Acuna P, George M, Pope E, Ito S, Shear N, Koren G, Shannon MW, Garcia-Bournissen F. Recurrence and Long-term Outcome of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. *Pediatrics.*, 128:4; pp 723-28, 2011.

Nurmohamed L, Moretti ME, Schechter T, Einarson A, Johnson D, Lavigne SV, Erebara A, Koren G, **Finkelstein Y**. Outcome following high-dose methotrexate in pregnancies misdiagnosed as ectopic. *Am J Obstet Gynecol.*; 205 (6): 533 e1-3, 2011.

Schechter T, Kirton A, Laughlin S, Pontigon AM, **Finkelstein Y**, Macgregor D, Chan A, Deveber G, Brandão LR. Safety of anticoagulants in children with arterial ischemic stroke. *Blood*. 2011. [Epub ahead of print]

Lin D, Seabrook JA, Matsui DM, King SM, Rieder MJ, **Finkelstein Y**. Palatability, Adherence and Prescribing Patterns of Antiretroviral Drugs for Children with Human Immunodeficiency Virus Infection in Canada. *Pharmacoepidemiology and Drug Safety.*; 20(12): 1246-52, 2011.

George SR

Kong M, Verma V, O'Dowd BF and **George SR**. The role of palmitoylation in directing dopamine D1 receptor internalization through selective endocytic routes. *Biochemical Biophysical Research Communications*. 405: 445-449, 2011.

Sromek S, Si Y-G, Zhang T, **George SR**, et al. Synthesis and biological evaluation of N-Fluoroalkyl and 2-Fluoroalkoyl substituted aporphines: Fluporphine, a potential PET ligand for dopamine D2 receptors. *ACS Medicine Chemistry Letters*. 2:189-194, 2011.

Kong MM, Verma V, O'Dowd BF and **George SR**. The role of palmitoylation in directing dopamine D1 receptor internalization through selective endocytic routes. *Biochemical Biophysical Research Communications*. 405: 445-449, 2011.

O'Dowd BF, Ji X, Alijaniam M, Nguyen T and **George S.R**. Separation and reformation of cell surface dopamine receptor oligomers visualized in cells. *European J Pharmacology*. 658: 74-83, 2011.

Perreault ML, O'Dowd BF and **George SR**. Dopamine receptor oligomers in schizophrenia. *CNS Neuroscience and Therapeutics*. *Schizophrenia Issue* 17:52-57, 2011.

Hasbi A, O'Dowd BF and **George SR**. Dopamine D1-D2 receptor heteromer signaling pathway in brain: Emerging physiological relevance. *Molecular Brain*. 4:26, 2011.

Perreault ML, Hasbi A, O'Dowd BF. and **George SR**. The dopamine D1-D2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in basal ganglia. *Frontiers in Neuroanatomy*. 5:31, 2011.

Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Weinberger DR, Karayiorgou M, Guidotti A, Gingrich J, Akbarian S, Buchanan RW, Lieberman JA, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Saw A, Caron MG, **George SR**,

Allen JA, Solis M. Advancing drug discovery for schizophrenia. *Annals N Y Academy Sciences*. 1236:30-43, 2011.

Hasbi A, O'Dowd BF, **George SR**. Signaling of dopamine receptor homo- and heterooligomers. In: *G protein-coupled receptors: Structure, Signaling and Physiology*, Cambridge Univ. Press, 2011.

Goldstein BI

Goldstein TR, **Goldstein BI**, Mantz MB, Bailey B, Douaihy A. A brief motivational intervention for preventing medication-associated weight gain among youth with bipolar disorder: treatment development and case report. *J Child Adolescent Psychopharmacology*; 21:275-280, 2011.

Goldstein BI, Collinger KA, Lotrich F, Marsland AL, Gill MK, Axelson DA, Birmaher B. Preliminary findings regarding pro-inflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. *Op cit*. 21:479-484, 2011.

George E, Taylor D, **Goldstein BI**, Miklowitz. Family focused therapy for bipolar adolescents: lessons from a difficult treatment case. *Cognitive and Behavioral Practice*; 18:384-393, 2011.

Goldstein TR, Obreja M, Shamseddeen W, Iyengar S, Axelson DA, **Goldstein BI**, et al. Risk for suicidal ideation among the offspring of bipolar parents: results from the bipolar offspring study (BIOS). *Archives of Suicide Research*; 15:207-222, 2011.

Goldstein BI, Liu SM, Zivkovic N, Schaffer A, Chien LC, Blanco C. The burden of obesity among adults with bipolar disorder in the United States. *Bipolar Disorders*; 13:387-395, 2011.

Axelson DA, Birmaher B, Findling RL, Fristad MA, Kowatch RA, Youngstrom EA, Arnold EL, **Goldstein BI**, et al. Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the Diagnostic and Statistical Manual of Mental Disorders, *J Clinical Psychiatry*; 50:1001-1016, 2011.

Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, **Goldstein BI**, Harvey A, Laghrissi-Thode F, Leboyer M, Ostacher MJ, Sibille E, Strakowski SM, Suppes T, Tohen M, Yolken RH, Young LT, Zarate CA. Advances in bipolar disorder: the 2011 Int Conf on Bipolar Disorder. *Annals NY Academy Sciences*; 1242:1-25, 2011.

Diler RS, Axelson DA, Goldstein TR, **Goldstein BI**, et al. Dimensional psychopathology in offspring of parents with bipolar disorder. *Bipolar Disorders*; 13:670-8, 2011.

Axelson DA, Birmaher B, Strober MA, **Goldstein BI**, et al. Course of subthreshold bipolar disorder in youth: diagnostic progression from bipolar disorder not otherwise specified. *J American Academy Child Adolescent Psychiatry*; 50:1001-16, 2011.

Bella T, Goldstein TR, Axelson D, Obreja M, Monk K, Hickey MB, **Goldstein B**, et al. Psychosocial functioning in offspring of parents with bipolar disorder. *J Affective Disorders*; 133:234-11, 2011.

Grant DM

Sugamori KS, Brenneman D, Sanchez O, Doll MA, Hein DW, Pierce WM Jr, **Grant DM**. Reduced 4-aminobiphenyl-induced liver tumorigenicity but not DNA damage in arylamine N-acetyltransferase null mice. *Cancer Lett*. 2011. [Epub ahead of print].

Sugamori KS, Brenneman D, **Grant DM**. Liver-selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice. *Drug Metab Dispos.*; 39(5):882-90, 2011.

Grant DM. Book Review: "Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory". *Clin Pharmacol Ther.* 90:358-359, 2011.

Haas DA

Haas DA. The dental team approach to medical emergencies. *Inside Dentistry*. 117. March 2011.

Becker DE and **Haas DA**. Management of complications during moderate and deep sedation. part 1: respiratory considerations. *Anesthesia Progress* 58: 82-92, 2011.

Haas DA. Alternative Mandibular Block Techniques. *Journal of the American Dental Association*. Sep 2011, 142 Suppl 3:8S-12S.

Becker DE and **Haas DA**. Recognition and management of complications during moderate and deep sedation. Part 2: cardiovascular considerations. *AnesthProg*. 2011 Fall;58(3):126-38.

Hamadanizadeh SA

Sukhai MA, Thomas M, **Hamadanizadeh SA**, Xuan Y, Wells RA, Kamel-Reid S. Correlation among nuclear localization of NuMA-RAR α , deregulation of gene expression and leukemic phenotype of hCG-NuMA-RAR α transgenic mice. *Leuk Res.*; 5(5):670-6, 2011

Hampson D

Pacey LK, Doss L, Cifelli C, van der Kooy D, Heximer SP, **Hampson DR**. Genetic Deletion of Regulator of G-protein Signaling 4 (RGS4) Rescues a Subset of Fragile X Related Phenotypes in the FMR1 Knockout Mouse. *Mol Cell Neurosci*. 2011 Mar; 46 (3): 563-72.

Broussard DM, Titley HK, Antflick J, **Hampson DR**. Motor learning in the VOR: the cerebellar component. *Exp Brain Res* 210 (3-4), 451-463, 2011.

Hampson DR, Adusei DC, Pacey LK. The Neurochemical Basis for Treating Autism Spectrum Disorders and Fragile X Syndrome. *Biochem Pharmacol* 81, 1078-1086, 2011.

Pacey LK, Tharmalingam S, **Hampson DR**. Subchronic Administration and Combination Metabotropic Glutamate and GABA_B Receptor Drug Therapy in Fragile X Syndrome. *J Pharmacol Exp Therap*, 338, 897 – 905, 2011.

Tharmalingam S, Daulat AM, Antflick JE, Ahmed SM, Nemeth EF, Angers S, Conigrave AD, **Hampson DR**. The Calcium-sensing Receptor Modulates Cell Adhesion and Migration via Integrins. *J Biol Chem* 286 (47), 40922-933, 2011.

Higgins G

Lu SX, **Higgins GA**, Hodgson RA, et al. The anxiolytic-like profile of the nociceptin NOP receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-zabicyclo[3.2.1]octane-3-carboxamide (SCH655842): comparison of efficacy and side-effects across rodent species. *Eur. J. Pharmacol.*; 661: 63-71, 2011.

Fletcher PJ, Rizos Z, Noble K, **Higgins GA**. Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT_{2C} receptor stimulation and 5-HT_{2A} receptor blockade. *Neuropharmacology*; 61: 468-477, 2011.

Fletcher PJ, **Higgins GA**. Serotonin and reward related behaviours: focus on 5-HT_{2C} receptors. In: *The Pathophysiology of central 5-HT_{2C} receptors*. Di Matteo V, Esposito E, Di Giovanni G (Eds).2011; Humana Press/Springer, New York, USA.

Ito S

Panchaud A, Garcia-Bournissen F, Csajka C, Kristensen JH, Taddio A, Ilet KF, Begg EJ, **Ito S**. Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine. *Clin Pharmacol Ther.*; 89: 830–836, 2011.

Blankier S, McCrindle BW, **Ito S**, Yeung RSM. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. *Clin Exp Immunology*; 164:193-201, 2011.

Ito S. A new dimension of clinical pharmacology: induced pluripotent stem cells. *Clin Pharmacol Ther.*; 89:629-632, 2011.

Ito S. Placebo in clinical trials. *Clin Pharmacol Ther.*; 90:637-639, 2011.

Finkelstein Y, Soon GS, Acuna P, George M, Pope E, **Ito S**, Shear NH, Koren G, Shannon MW, Garcia-Bournissen F. Recurrence and Long-Term Outcome of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. *Pediatrics*; 128: 723-728, 2011.

Visscher H, Ross CJD, Rassekh R, Barhdadi A, et al. and Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. *J Clin Oncol.*; 10.1200/JCO.2010.34.3467. 2011

Ito S. Pharmacokinetics 101. *Paed Child Health*;16:535-536, 2011.

MacLeod S, **Ito S**. Walking the tightrope. *Paed Child Health*; 16: 527, 2011.

Kish SJ

Mann A, Miksys SL, Gaedigk A, **Kish SJ**, Mash DC, Tyndale RF. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. *Neurobiol Aging*. 2011. [Epub ahead of print]

Bacher I, Houle S, Xu X, Zawertailo L, Soliman A, Wilson AA, Selby P, George TP, Sacher J, Miler L, **Kish SJ**, et al. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. *Arch Gen Psychiatry*.; 68(8): 817-26, 2011.

Callaghan RC, Cunningham JK, Sykes J, **Kish SJ**. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. *Drug Alcohol Depend.*; 120(1-3):35-40, 2011.

Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, Houle S, **Kish SJ**. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. *J Cereb Blood Flow Metab.*; 31(10):2065-75, 2011.

Tong J, Furukawa Y, Sherwin A, Hornykiewicz O, **Kish SJ**. Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain. *Neurobiol Dis.* ; 41(2):458-68, 2011.

Koren G (59)

Koren G, Nulman I, Aleksa K, Gareri J, Einarson A, Ito S. Essay for the 2011 CIHR/CMAJ award: Motherisk -- caring for mothers, protecting the unborn. *CMAJ*.

Koren G, Nordeng H. SSRIs and persistent pulmonary hypertension of the newborn. *BMJ*; 12;344:d7642. doi: 10.1136/bmj.d7642, 2011.

Aleksa K, Liesivuori J, **Koren G**. Hair as a biomarker of polybrominated diethyl ethers' exposure in infants, children and adults. *Toxicol Lett*. 2011.

Moretti ME, Caprara D, Drehuta I, Yeung E, Cheung S, Federico L, **Koren G**. The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. *Obstet Gynecol Int*; 658310. , 2011.

Yazdani Brojeni P, Matok I, Garcia Bournissen F, **Koren G**. A systematic review of the fetal safety of interferon alpha. *Reprod Toxicol*. 2011 Dec 19. [Epub ahead of print].

Gedeon C, Nava-Ocampo AA, **Koren G**. Ethical issues in pharmacologic research in women undergoing pregnancy termination: a systemic review and survey of researchers. *Obstet Gynecol Int.*; 24591. Epub 2011 Nov 30.

Moretti ME, **Koren G**, Finkelstein Y. Reply. *Am J Obstet Gynecol*. [Epub ahead of print] PubMed PMID: 22182681, 2011.

Natekar A, Pupco A, Bozzo P, **Koren G**. Safety of azathioprine use during pregnancy. *Can Fam Physician.*; 57(12):1401-2, 2011.

Hutson JR, **Koren G**. Response to "Intrauterine exposure to thiopurines". *Reprod Toxicol.* 2011
PubMed PMID: 22155439, 2011. [Epub ahead of print]

Lara-Corrales I, Parkin PC, Stephens D, Hamilton J, **Koren G**, Weinstein M, Sibbald RG, Pope E. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: A feasibility trial. *J Am Acad Dermatol.*; 66(2):264-70, 2011.

Walfisch A, Sermer C, Matok I, Einarson A, **Koren G**. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression. *Can J Psychiatry* ;56(12):761-7, 2011.

Ross LE, Grigoriadis S, Mamisashvili L, **Koren G**, et al. Quality assessment of observational studies in psychiatry: an example from perinatal psychiatric research. *Int J Methods Psychiatr Res.*; 20(4):224-34. doi: 10.1002/mpr.356, 2011.

Koren G. Pharmacokinetics in pregnancy; clinical significance. *J Popul Ther Clin Pharmacol.*; 18(3):e523-7, 2011.

Koren G. Hypertension: ACE inhibitor use in pregnancy--setting the record straight. *Nat Rev Cardiol.*; 9(1):7-8. doi: 10.1038/nrcardio.2011.179.

Aleksa K, Carnevale A, Goodyer C, **Koren G**. Detection of polybrominated biphenyl ethers (PBDEs) in pediatric hair as a tool for determining in utero exposure. *Forensic Sci Int*, 2011 [Epub ahead of print].

Klieger-Grossmann C, Weitzner B, Panchaud A, Pistelli A, Einarson T, **Koren G**, Einarson A. Pregnancy Outcomes Following Use of Escitalopram: A Prospective Comparative Cohort Study. *J Clin Pharmacol*, 2011. [Epub ahead of print]

Einarson A, Choi J, **Koren G**, Einarson T. Outcomes of infants exposed to multiple antidepressants during pregnancy: results of a cohort study. *J Popul Ther Clin Pharmacol.*; 18(2):e390-6, 2011.

Aleksa K, Walasek P, Fulga N, Kapur B, Gareri J, **Koren G**. Simultaneous detection of seventeen drugs of abuse and metabolites in hair using solid phase micro extraction (SPME) with GC/MS. *Forensic Sci Int.* 2011 Nov 1. [Epub ahead of print] PubMed PMID: 22047752.

Stade B, Beyene J, Buller K, Ross S, Patterson K, Stevens B, Sgro M, Ungar W, Watson W, **Koren G**. Feeling different: the experience of living with fetal alcohol spectrum disorder. *J Popul Ther Clin Pharmacol.*; 18(3):e475-85, 2011.

Vandervaart S, Berger H, Tam C, Goh YI, Gijzen VM, de Wildt SN, Taddio A, **Koren G**. The effect of distant reiki on pain in women after elective Caesarean section: a double-blinded randomised controlled trial. *BMJ Open.*;1 (1):e000021, 2011.

Lanctôt KL

Herrmann N, **Lanctôt KL**. Long-term use of cholinesterase inhibitors: till death do us part? *Neurodegen Dis Manage*, 1(1):7-9, 2011.

Gold A, Herrmann N, **Lanctôt KL**. Lithium and its neuroprotective and neurotrophic effects: potential treatment for post-stroke sequelae. *Current Drug Targets* 1;12(2):243-55, 2011.

Gold AB, Herrmann N, Swardfager WL, Black SE, Aviv RI, Tennen G, Kiss A and **Lanctôt KL**. The relationship between IDO activity and post-stroke cognitive impairment. *J Neuroinflamm*;8:17, 2011.

Herrmann N, Black SE, Li A, **Lanctôt KL**. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. *Int Psychogeriatrics*; 23(4):539-45 , 2011.

Herrmann N, Li A, **Lanctôt KL**. Memantine in dementia: a review of the current evidence. *Expert Opin Pharmacother*; 12(5):787, 2011.

Herrmann N, Cappell J, Eryavec G, **Lanctôt KL**. Changes in nursing burden following memantine for agitation and aggression in long term care residents with moderate to severe Alzheimer's disease. *CNS Drugs*, 1 ;25(5):425-33, 2011.

Smart K, Herrmann N, **Lanctôt KL**. Validity and responsiveness to change of clinically-derived MDS scales in Alzheimer's disease outcomes research. *J Geriatr Psychiatry Neurol*, 24(2):67-72, 2011.

Mitchell I, Paes B, Li A, **Lanctôt KL**. CARESS: the Canadian registry of palivizumab. *Pediatr Infect Dis J.*; 30(8):651-5, 2011.

Swardfager WL, Herrmann N, Marzolini S, Saleem M, Shammi P, Oh PI, Albert P, Daigle M, Kiss A, **Lanctôt KL**. Brain derived neurotrophic factor, fitness and cognition in coronary artery disease. *Brain Behav Immun*, 25(6): 1264–71, 2011.

Swardfager WL, Herrmann N, Marzolini S, Oh PI, Saleem M, Shammi P, Kiss A, Cappell J, **Lanctôt KL**. Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery disease. *Psychosom Med*, 1; 73(7):580-7, 2011.

Pinto T, Herrmann N, **Lanctôt KL**. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. *Ageing Res Rev.*; 10(4):404-12, 2011.

Swardfager WL, Herrmann N, Marzolini S, Saleem M, Farber S, Kiss A, Oh PI, **Lanctôt KL**. Major depressive disorder predicts completion, adherence and outcomes in cardiac rehabilitation: a prospective cohort study of 195 patients with coronary artery disease. *J Clin Psychiatry*; 72(9):1181-8, 2011.

Mitchell RA, Herrmann N, **Lanctôt KL**. The role of dopamine in symptoms and treatment of apathy in Alzheimer's Disease. *CNS Neurosci Therapeutics*, 17(5):411-27, 2011.

Herrmann N, Chau S, Kircanski I, **Lanctôt KL**. Current and emerging treatment options for Alzheimer's disease. *Drugs*, 22;71(15):2031-65, 2011.

Tennen G, Herrmann N, Black SE, Levy KS, Cappell J, Li A and **Lanctôt KL**. Are vascular risk factors associated with post-stroke depressive symptoms? *J Geriatr Psychiatry Neurol*, 24(4):215-21, 2011.

Laposa R

Laposa RR. Stem cells for drug screening. *J Cardiovasc Pharmacol*; 58(3):240-5. 2011.

Lê AD

Lê AD, Funk D, Juzytsch W, et al. Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. *Psychopharmacol (Berl)* 18(1):89-99, 2011.

Lê AD, Funk D, Coen K, Li Z, Shaham Y. Role of corticotropin-releasing factor in the median raphe nucleus in yohimbine-induced reinstatement of alcohol seeking in rats. *Addict Biol*. 2011 Oct 4. doi: 10.1111/j.1369-1600.2011.00374.x. [Epub ahead of print]

Rehm J, Giesbrecht N, Gliksman L, Graham K, **Le AD**, et al. Addiction Research Centres and the Nurturing of Creativity. Substance abuse research in a modern health care centre: the case of the Centre for Addiction and Mental Health. *Addiction.*; 06(4):689-97, 2011.

Le Foll B

Gamaledin I, Guranda M, Goldberg SR, **Le Foll B**. The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake. *Br J Pharmacol.*; 164(6):1652-60, 2011.

Le Foll B, Chakraborty-Chatterjee M, Lev-Ran S, et al. Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. *Int J Neuropsychopharmacol*. 23:1-10, 2011.

Le Strat Y, Dubertret C, **Le Foll B**. Prevalence and correlates of major depressive episode in pregnant and postpartum women in the United States. *J Affect Disord.*; 135(1-3):128-38, 2011.

Le Strat Y, Dubertret C, **Le Foll B**. Child Marriage in the United States and Its Association With Mental Health in Women. *Pediatrics*; 28. [Epub ahead of print], 2011.

Le Strat Y, **Le Foll B**. Obesity and cannabis use: results from 2 representative national surveys. *Am J Epidemiol.*; 174(8):929-33, 2011.

Le Strat Y, Rehm J, **Le Foll B**. How generalisable to community samples are clinical trial results for treatment of nicotine dependence: a comparison of common eligibility criteria with respondents of a large representative general population survey. *Tob Control.*; 20(5):338-43, 2011.

Leggio GM, Micale V, **Le Foll B**, Mazzola C, Nobrega JN, Drago F. Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam. *Eur Neuropsychopharmacol.*; 21(4):325-32, 2011.

Lev-Ran S, Le Strat Y, **Le Foll B**. Impact of hypertension and body mass index on quality of life in schizophrenia. *Am J Psychiatry*; 168(5):552-3, 2011.

Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, Redhi GH, Yasar S, **Le Foll B**, et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. *Biol Psychiatry.*; 9(7):633-41, 2011.

MacDonald JF

Xie YF, Belrose JC, Lei G, Tymianski M, Mori Y, **Macdonald JF**, Jackson MF. Dependence of NMDA/GSK-3 β mediated metaplasticity on TRPM2 channels at hippocampal CA3-CA1 synapses. *Mol Brain.* 21; 4:44, 2011.

Yang K, Trepanier C, Sidhu B, Xie YF, Li H, Lei G, Salter MW, Orser BA, Nakazawa T, Yamamoto T, Jackson MF, **Macdonald JF**. Metaplasticity gated through differential regulation of GluN2A versus GluN2B receptors by Src family kinases. *EMBO J.* doi: 10.1038/emboj.2011.

Trepanier CH, Jackson MF, MacDonald JF. Regulation of NMDA receptors by the tyrosine kinase Fyn. *FEBS J.* (1):12-9. doi: 10.1111/j.1742-4658.2011.08391.x. Epub 2011.

Yang K, Belrose J, Trepanier CH, Lei G, Jackson MF, **MacDonald JF**. Fyn, a potential target for Alzheimer's disease. *J Alzheimers Dis*; 27(2):243-52, 2011.

Chen X, Whissell P, Orser BA, **MacDonald JF**. Functional modifications of acid-sensing ion channels by ligand-gated chloride channels. *PLoS One.*; 6(7):e21970. 2011.

Li HB, Jackson MF, Yang K, Trepanier C, Salter MW, Orser BA, **Macdonald JF**. Plasticity of synaptic GluN receptors is required for the Src-dependent induction of long-term potentiation at CA3-CA1 synapses. *Hippocampus*; 21(10):1053-61. doi: 10.1002/hipo.20818. Epub 2010 Jun 2. PubMed PMID: 20865743.

Matthews J

Lo, R., Forgacs, A., Celius, T., MacPherson, L., Harper, P., Zacharewski, T., and **Matthews, J. (SRA)**. Genome-wide Analysis of Aryl Hydrocarbon Receptor Binding Targets in Dioxin-Treated Mouse Hepatic Tissue. *Toxicol Appl Pharmacol* 257(1):38-47, 2011.

Dere, E., Lo, R., Celius, T. **Matthews, J. (COLL)**, and Zacharewski, T. Integration of Genome-Wide Computation DRE Search, AhR ChIP-chip and Gene Expression Analyses of TCDD-Elicited Responses in the Mouse Liver. *BMC Genomics* 12(1):365, 2011

Powis, M., Celius, T., and **Matthews, J. (SRA)**. Ligand-dependent coactivator recruitment and a role for Y322 in aryl hydrocarbon receptor-mediated transcription. *Biochem Biophys Res Comm.* 410(4):859-65, 2011.

McIntyre RS

McIntyre RS. Asenapine: A Review of Acute and Extension Phase Data in Bipolar Disorder. *CNS Neurosci Therap*; 17:645-648, 2011.

Rowe J, Cadzow RB, **McIntyre RS**, Paterson, J, Kellam C. Understanding the “Concept of Noise” in Mental Health Care Encounters With Patients From Different Cultures. *Home Health Care Management & Practice*: 1-7, 2011.

McIntyre RS. Implementing guideline-based strategies to avoid relapse and recurrence in depression. *J Clin Psychiatry*; 72(11):e35, 2011.

Jerrell JM, Tripathi A, **McIntyre RS (CO-PA)**. Prevalence and Treatment of Depression in Children and Adolescents With Sickle Cell Disease: A Retrospective Cohort Study. *Prim Care Companion CNS Discord*; 13, 2011.

Jerrell JM, **McIntyre RS**, Tripathi A. Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. *Hum Psychopharmacol*; 26(7):451-459, 2011.

Kahn LS, **McIntyre RS**, Rafalson L, Berdine DE, Fox CH. Fasting Blood Glucose and Depressive Mood among Patients with Mental Illness in a Medicaid Managed Care Program. *Depress Res Treat* 2011.

Brietzke E, Kapczynski F, Grassi-Oliveira R, Grande I, Vieta E, **McIntyre RS (SRA)**. Insulin dysfunction and allostatic load in bipolar disorder. *Expert Rev Neurother.*; 11(7):1017-28.

McIntyre RS, McElroy SL, Eudicone JM, Forbes RA, Carlson BX, Baker RA. A 52-Week, Double-Blind Evaluation of the Metabolic Effects of Aripiprazole and Lithium in Bipolar I Disorder. *Primary Care Companion CNS Disorders*; 13(6):e1-7, 2011.

Kurnianingsih YA, Kuswanto CN, **McIntyre RS (CA)**, Qiu A, Ho BC, Sim K. Neuro Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. *J Neural Transm.* 2011 Jun 19. [Epub ahead of print]

McIntyre RS (SRA), Yoon J, Jerrell JM, Liauw SS. Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. *Neuropsychiatric Disease and Treatment*; 7:319-323, 2011.

Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, **McIntyre RS (SRA)**. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. *Eur Psychiatry*. May 2011.

Ahmed AT, Blair TR, **McIntyre RS (CO-PA)**. Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda. *Adv Ther*; 28(5):389-400, 2011.

Wiwanitkit V, Jerrell JM, **McIntyre RS (CO-PA)**, Tripathi A. Cardiometabolic conditions in patients with Schizophrenia. *Clin Schizophr Relat Psychoses*; 5(1):54, 2011.

Kahn LS, **McIntyre RS (CO-PA)**, Rafalson L, et al. Fasting Blood Glucose and Depressive Mood among Patients with Mental Illness in a Medicaid Managed Care Program. *Depression Res Treatment*. April 2011.

McPherson JP

H. Sarras and **J.P. McPherson**. "The cellular response to Chromium (VI) – induced DNA damage." In "Chromium: Environmental, Medical and Materials Studies." Nova Publishers, New York. 2011.

Meyer JH

Vasdev N, Sadovski O, Moran MD, Parkes J, **Meyer JH**, Houle S, Wilson AA. Development of new radiopharmaceuticals for imaging monoamine oxidase B. *Nucl Med Biol.*; 38(7):933-43, 2011.

Bacher I, Houle S, Xu X, Zawertailo L, Soliman A, Wilson AA, Selby P, George TP, Sacher J, Miler L, Kish SJ, Rusjan P, **Meyer JH**. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. *Arch Gen Psychiatry.*; 68(8):817-26, 2011.

Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, **Meyer JH**, Houle S, Mizrahi R. Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography. *J Cereb Blood Flow Metab.* 2011 Aug;31(8):1807-16. doi: 10.1038/jcbfm.2011.

Sacher J, Rabiner EA, Clark M, Rusjan P, Soliman A, Boskovic R, Kish SJ, Wilson AA, Houle S, **Meyer JH**. Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study. *Op cit.* 32(3):443-6. doi: 10.1038/jcbfm.2011.

Sacher J, Houle S, Parkes J, Rusjan P, Sagrati S, Wilson AA, **Meyer JH**. Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John's wort: an [11C]-harmine PET study. *J Psychiatry Neurosci.*; 36(6):375-82, 2011.

Soliman A, Bagby RM, Wilson AA, Miler L, Clark M, Rusjan P, Sacher J, Houle S, **Meyer JH**. Relationship of monoamine oxidase A binding to adaptive and maladaptive personality traits. *Psychol Med.*; 41(5):1051-60, 2011.

Milgram NW

Araujo JA, Greig NH, Ingram DK, Sandin J, de Rivera C, **Milgram NW**. Cholinesterase inhibitors improve both memory and complex learning in aged beagledogs. *J Alzheimers Dis.*; 6(1):143-55. 2011.

Araujo JA, Nobrega JN, Raymond R, **Milgram NW**. Aged dogs demonstrate both increased sensitivity to scopolamine impairment and decreased muscarinic receptor density. *Pharmacol Biochem Behav.*; 98(2):203-9, 2011.

Snigdha S, Christie LA, De Rivera C, Araujo JA, **Milgram NW**, Cotman CW. Age and distraction are determinants of performance on a novel visual search task in aged Beagle dogs. *Age (Dordr)*. 2011 Feb 19. [Epub ahead of print]

Collison KS, Zaidi MZ, Saleh SM, Inglis A, Mondreal R, Makhoul NJ, Bakheet R, Burrows J, **Milgram NW**, Al-Mohanna FA. (2011). Effect of trans-fat, fructose and monosodium glutamate feeding on feline weight gain, adiposity, insulin sensitivity, adipokine and lipid profile. *Br J Nutr.* 1-10, 2011. [Epub ahead of print]

Mitchell J

Mitchell J, Lai LP, Peralta F, Xu Y, Sugamori K. β_2 -Adrenergic Receptors Inhibit the Expression of Collagen Type II in Growth Plate Chondrocytes by Stimulating the AP-1 Factor Jun-B. *Am J Physiol Endocrinol Metab*. 2011.

Mittmann N

Sud S, **Mittmann N**, Cook D, et al. On Behalf of the E-PROTECT Investigators and the Canadian Critical Care Trials Group. Screening and Prevention for Venous thromboembolism in Critically Ill Patients: A Decision Analysis and Economic Evaluation. *Am J Resp Critical Care Medicine*; 84 (11): 1289-98, 2011.

Mittmann N, Hernandez P, Mellström C, et al. Cost-effectiveness of budesonide/formoterol added to tiotropium versus placebo added to tiotropium in COPD patients from Australian, Canadian and Swedish healthcare perspectives. *Pharmacoeconomics*; 29 (5): 403-414, 2011.

Nanwa N, **Mittmann N**, Knowles S, et al. The direct medical costs associated with suspected heparin-induced thrombocytopenia. *Op cit*; 29(6): 511-520, 2011.

Mittmann N, Chan BC, Craven BC, et al. Cost-effectiveness of electrical stimulation therapy for pressure ulcers in spinal cord injury. *Arch Physical Med Rehabilitation*; 92(6): 866-872, 2011.

Mittmann N, Seung SJ. Rash Rates with EGFR Inhibitors: Meta-analysis. *Current Oncology*; 18(2). Epub e54-e6, 2011 .

Bernard LM, Verma S, Thompson M, **Mittmann N**, et al. Docetaxel plus cyclophosphamide is cost-effective versus doxorubicin plus cyclophosphamide in the adjuvant treatment of operable

breast cancer: A Canadian economic analysis of US Oncology Adjuvant Trial 9735. *Current Oncology*; 18 (2): 67-75, 2011.

Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, Rourke S, Rueda S, Rachlis A, **Mittmann N**, et al. Once daily dosing improves adherence to antiretroviral therapy. *AIDS & Behavior*; 15 (7):1397-409, 2011.

Neuman MG

Neuman MG, Oruña L, Nanau RM, Coto G. In vitro anti-inflammatory effects of hyaluronic acid in ethanol-induced damage in skin cells. *J Pharm Pharmaceutical Sc*, 14(3), 425-437, 2011.

Neuman, MG., Schmilowitz-Weiss H, Hilzenrat N, et al. Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C. *World J Hepatol*, special issue on Alcoholic Hepatitis, doi:10.1155/2012/231210. 2011.

Neuman MG and Nanau RM. Diet and life style in inflammatory bowel disease. *Translational Research*, 156, Special Issue on Inflammatory Bowel Disease and Metabolomics, 2011.
Nanau MR and **Neuman MG**. Metabolomics in inflammatory bowel disease. *Op cit.* 2011; 1-23; doi. 10.1016/j.trl.08.006, 2011

Nobrega JN

Creed MC, Hamani C, **Nobrega JN**. Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: Comparison with transient local inactivation. *Eur Neuropsychopharmacol.*; 2(7):506-17, 2011.

Hamani C, Machado DC, Hipólido DC, Dubiela FP, Suchecki D, Macedo CE, Tescarollo F, Martins U, Covolan L, **Nobrega JN**. Deep brain stimulation reverses anhedonic-like behavior in a chronic model of depression: role of serotonin and brain derived neurotrophic factor. *Biol Psychiatry.*; 71(1):30-5, 2011.

Remington G, Mann S, McCormick P, **Nobrega JN**, Hahn M, Natesan S. Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations. *Pharmacol Biochem Behav.*; 100(1):86-9, 2011.

Creed-Carson M, O raha A, **Nobrega JN**. Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. *Behav Brain Res.*; 219(2):273-9, 2011.

Araujo JA, **Nobrega JN**, Raymond R, Milgram NW. Aged dogs demonstrate both increased sensitivity to scopolamine impairment and decreased muscarinic receptor density. *Pharmacol Biochem Behav.*; 98(2):203-9, 2011.

Brown ZJ, **Nobrega JN**. Erb S. Central injections of noradrenaline induce reinstatement of cocaine seeking and increase c-fos mRNA expression in the extended amygdala. *Behavioural Brain Research*, 217, 472-476, 2011.

Troncone LRP, Ravelli KG, Magnoli FC, Lebrun I, Hipolide DC, Raymond R, **Nobrega JN**. Regional brain c-fos activation associated with penile erection and other symptoms induced by the spider toxin Tx2-6. *Toxicon*, 58, 202-208, 2011.

Leggio GM, Micale V, Le Foll B, Mazzola C, **Nobrega JN**, Drago F. Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam. *European Neuropsychopharmacology*, 21, 325-332, 2011.

Dubiela FP, Messias MF, Moreira KD, Grassl C, Frussa Filho R, **Nobrega JN**, Tufik S, Hipólido DC. Reciprocal interactions between MK-801, sleep deprivation and recovery in modulating behavior in the rat. *Behavioural Brain Research*, 216, 180-185, 2011.

O'Brien PJ

Bruce WR, Lee O, Liu Z, Marcon N, Minkin S, **O'Brien PJ**. Biomarkers of exposure to endogenous oxidative and aldehyde stress. *Biomarkers* 16 (5) 453-6, 2011.

MacAllister S, Choi J, Dedina L and **O'Brien PJ**. Methanol/Formaldehyde Metabolic Activation causing Hepatocyte Cytotoxicity: Carbonyl-Metabolising Enzymes versus Oxidative stress. *Chemico-Biol.Interactions* 191 308-314, 2011.

Chan TS and **O'Brien PJ**. Chapter 16 "Nutritional Antioxidants" in "Principles of Free Radical Biomedicine" (in press) Ed. Pantapoulos Kostas. Nova Science Publishers, 2011.

Yang, K, Dong Q, Delaney SR, Mehta RRW, Bruce RW, **O'Brien PJ**. Differences in glyoxal and methylglyoxal metabolism determines cellular susceptibility to protein carbonylation and cytotoxicity. *Chemico-Biol.Interactions*, 191, 322-329, 2011.

Yang K, Feng C, Bruce RW, **O'Brien PJ**. Molecular cytotoxic and cytoprotection mechanisms for glyceraldehyde, hydroxypyruvate and glycolaldehyde in hepatocytes. *Op cit.* 191, 315-321, 2011.

Shuhendler AJ, Prasad P, Chan HC, Gordijo CR, Kolios SB, Yu K, **O'Brien PJ**, Rauth AM and Wu XY. Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant *in vivo* optical imaging of deep tissue. *Am Chem Soc Nano* 5(3)1958-66, 2011.

Wright J, Hoorman J, Durst T, Asim M, El-Salfiti M, Choueiri C, Pratt MA, Ruddy S, Lau R, Carlson K, Katzenellenbogen J, **O'Brien PJ**, Wan L, Anderson J. "A-CD Estrogens : 1. Substituent effects, hormone potency, and receptor subtype selectivity in a new family of flexible estrogenic compounds" *J Med Chem* 54 (2) 433-48, 2011.

O'Dowd BF

O'Dowd BF, Ji X, Nguyen T, George SR. Two amino acids in each of D1 and D2 dopamine receptor cytoplasmic regions are involved in D1-D2 heteromer formation. *Biochem Biophys Res Commun.*; 417(1):23-8. , 2011.

Perreault ML, Hasbi A, **O'Dowd BF**, George SR. The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia. *Front Neuroanat.*; 5:31, 2011.

Hasbi A, **O'Dowd BF**, George SR. Dopamine D1-D2 receptor heteromer signaling pathway in the brain: emerging physiological relevance. *Mol Brain.*; 4:26, 2011.

O'Dowd BF, Ji X, Alijanirram M, Nguyen T, George SR. Separation and reformation of cell surface dopamine receptor oligomers visualized in cells. *Eur J Pharmacol.*; 58(2-3):74-83, 2011.

Kong MM, Verma V, **O'Dowd BF**, George SR. The role of palmitoylation in directing dopamine D1 receptor internalization through selective endocytic routes. *Biochem Biophys Res Commun.*; 05(3):445-9, 2011.

Perreault ML, **O'Dowd BF**, George SR. Dopamine receptor homooligomers and heterooligomers in schizophrenia. *CNS Neurosci Ther.*; 7(1):52-7, 2011.

Ogilvie RI

Rabi DM, Daskulopoulou SS, Padwal RS et al including **Ogilvie RI**. The 2011 Canadian Hypertension Educational Program Recommendations for the Management of Hypertension: Blood Pressure Measurement, Diagnosis, Assessment of Risk, and Therapy. *Can J Cardiol.* 27:415-433, 2011.

Ogilvie RI. Drugs and People I Have Known: 45 Years in Clinical Pharmacology. *J Popul Ther Clin Pharmacol.*; 18:e455-e470, 2011.

Okey AB

Boutros PC, Yao CQ, Watson JD, Wu, AH, Moffat ID, Prokopek SD, Smith AB, **Okey AB** & Pohjanvirta R. Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. *Tox Applied Pharmacol* 251:119-129, 2011.

Boutros PC, Moffat ID, **Okey AB** & Pohjanvirta R. mRNA levels in control rat liver display strain-specific, hereditary and AHR-dependent components. *PloS ONE*, 6(7): e18337. doi:10.1371, 2011.

Pace-Asciak CR

Pace-Asciak CR. Hepoxilins in cancer and inflammation--use of hepoxilin antagonists. *Cancer Metastasis Rev.*;30(3-4):493-506, 2011.

Pang KS

Fan J, Maeng H-J, Du Y. Kwan D, **Pang KS**. Transport of 5,5-diphenylbarbituric acid and their effects on P-gp MRP2 and CYP3A4 in Caco-2 and LS180 Cells. *Eur J. Pharm Sci*, 42(1-2): 19-29, 2011.

Chow EC, Sondervan M, Jin C, Groothuis GM, **Pang KS**. Comparative effects of doxercalciferol (1 α -hydroxyvitamin D₂) vs. calcitriol (1 α ,25-dihydroxyvitamin D₃) on transporters and enzymes in the rat *in vivo*. *J Pharm. Sci* 100(4):1594-1604 (2011).

Khan AA, Chow EC, Porte RJ, **Pang KS**, Groothuis GM. The role of lithocholic acid in the regulation of bile acid detoxification, synthesis and transport proteins in rat and human intestine and liver slices. *Toxicol In Vitro* 25(1): 80–90, 2011.

Maeng HJ, Durk MR, Chow EC, Ghoneim R, **Pang KS**. 1 α ,25-Dihydroxyvitamin D₃ on intestinal transporter function: Studies with the rat everted intestinal sac. *Biopharm Drug Dispos* 32(2):112-25, 2011.

Chow EC, Durk MR, Cummin CL, **Pang KS**. 1 α ,25-Dihydroxyvitamin D₃ upregulates P-glycoprotein activities via the VDR and not in both *fxr*(-/-) and *fxr*(+/+) mice, and increased renal and brain efflux of digoxin in mice *in vivo*. *J Pharmacol Exp Ther* 337(3):846-59, 2011.

Pang KS, Rostami-Hodjegan A. Editorial Commentary: Fraction absorbed (F_{abs}): Different connotations and confusion for the literature?" *Biopharm Drug Dispos* 32(4):301-302 2011.

Park H-W

Wang H, Hota PK, Tong Y, Li B, Shen L, Nedyalkova L, Borthakur S, Kim S, Tempel W, Buck M, **Park HW**. Structural basis of Rnd1 binding to Plexin Rho GTPase binding domains (RBDs). *J Biol Chem* 286:26093-26106, 2011.

Kumaraswami M, Avanigadda L, Rai R, **Park HW**, Howe MM. Genetic analysis of phase Mu Mor amino acids involved in DNA minor groove binding and conformational changes. *Op cit.* 286:35852-35862, 2011.

Strushkevich N, MacKenzie F, Cherkesova T, Grabovec I, Usanov S, **Park HW**. Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system. *Proc Nat Acad Sci* 108:10139-10143, 2011.

Petronis A

Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, Dong A, Tempel W, Wang SC, Chen X, Chau I, Mangano TJ, Huang XP, Simpson CD, Pattenden SG, Norris JL, Kireev DB, Tripathy A, Edwards A, Roth BL, Janzen WP, Garcia BA, **Petronis A**, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. *Nat Chem Biol.* 2011; (8):566-74. doi: 10.1038/nchembio.599. Erratum in: *Nat Chem Biol.*; (9):648.

Tolg C, Sabha N, Cortese R, Panchal T, Ahsan A, Soliman A, Aitken KJ, **Petronis A**, Bägli DJ. Uropathogenic *E. coli* infection provokes epigenetic downregulation of CDKN2A (p16INK4A) in uroepithelial cells. *Lab Invest.*; 1(6):825-36, 2011.

Piquette-Miller M

Zahedi P, Stewart J, De Souza R, **Piquette-Miller M**, Allen C. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. *J Control Release.*; 158(3):379-85, 2011.

Cressman AM, Petrovic V, **Piquette-Miller M**. Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. *Expert Rev Clin Pharmacol.* ; 5(1):69-89, 2011.

Anger GJ, **Piquette-Miller M**. Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes. *Drug Metab Dispos.*;3 9(10):1850-9, 2011.

De Souza R, Zahedi P, Badame RM, Allen C, **Piquette-Miller M**. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. *Mol Cancer Ther.*; 10(7):1289-99, 2011.

Zahedi P, De Souza R, **Piquette-Miller M**, Allen C. Docetaxel distribution following intraperitoneal administration in mice. *J Pharm Pharm Sci.*; 14(1):90-9, 2011.

Zahedi P, De Souza R, Huynh L, **Piquette-Miller M**, Allen C. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer. *Mol Pharm.*; 8(1):260-9. , 2011.

Gahir SS, **Piquette-Miller M**. Gestational and pregnane X receptor-mediated regulation of placental ATP-binding cassette drug transporters in mice. *Drug Metab Dispos.*; 39:465-71, 2011.

Zahedi P, De Souza R, **Piquette-Miller M**. Optimizing cancer care: is the future bright? *Clin Pharmacol Ther.*; 90(3):347-50, 2011.

Pollock BG

Reynolds CF III, Butters MA, Lopez O, **Pollock BG**, et al. Maintenance treatment of depression in old age: A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant Pharmacotherapy. *Arch Gen Psychiatry* 68: 51-60, 2011.

Voineskos AN, Lerch JP, Felsky D, Shaikh S, Rajji TK, Miranda D, Lobaugh NJ, Mulsant BH, **Pollock BG**, Kennedy JL: The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. *Op cit.* 68: 198-206, 2011.

Nebes RD, **Pollock BG**, Halligan EM, et al. Cognitive slowing associated with elevated serum anticholinergic activity in older individuals is decreased by caffeine use. *Am J Geriatric Psychiatry* 19: 169-175, 2011.

Youngberg MR, Karpov IO, Begley A, **Pollock BG**, Buysse DJ: Clinical and physiological correlates of caffeine and caffeine metabolites in primary insomnia. *J Clin Sleep Med* 7: 196-203, 2011.

Bigos KL, Bies RR, **Pollock BG**, et al. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. *Molecular Psychiatry* 16: 620-625, 2011.

Gerretsen P, **Pollock BG**: Rediscovering adverse anticholinergic effects. *J Clin Psychiatry* 72: 869-870, 2011.

Feng Y, Gastonguay MR, **Pollock BG**, et al. Performance of the Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy. *Neuropsych Disease Treatment* 7: 117-125, 2011.

Chow TW, Graff-Guerrero A, Verhoeff PG, Binns M, Tang-Wai T, Massellis M, Black SE, Freedman M, Wilson A, Houle S, **Pollock BG**: Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. *Op cit.* 7: 415-424, 2011.

Gerretsen P, **Pollock BG**: Drugs with anticholinergic properties: A current perspective on use and safety. *Expert Opinion on Drug Safety* 10: 751-765, 2011.

Gerretsen P, Diaz P, Mamo D, Kavanagh D, Menon M, **Pollock BG**, Graff-Guerrero A: Transient insight induction with electroconvulsive therapy in a patient with refractory schizophrenia: A case report and systematic literature review. *Journal of ECT* 27: 247-250, 2011.

Wessels AM, Bies RR, **Pollock BG**, et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. *J Clin Pharmacol* 51: 1587-1591, 2011.

D'Souza R, Rajji TK, Mulsant BH, **Pollock BG**: Use of lithium in the treatment of bipolar disorder in late-life. *Current Psychiatry Reports* 13: 488-492, 2011.

Voineskos AN, Lerch JP, Felsky D, Tiwari A, Rajji TK, Miranda D, Lobaugh NJ, **Pollock BG**, Mulsant BH, Kennedy JL: The ZNF804A gene: Characterization of a novel neural mechanism for major psychoses. *Neuropsychopharmacology* 9:1871-8, 2011.

Uchida H, Chow TW, Mamo DC, Kapur S, Mulsant BH, Houle S, **Pollock BG** Graff-Guerrero A: Effects of aging on 5-HT_{2A}R binding: A HRRT PET study with and without partial volume corrections. *Int J Geriatr Psych* 26:1300-8, 2011.

Pollock BG, Mulsant BH: Between Scylla and charybdis: Antipsychotic and other psychotropic medications in older nursing home residents. *Can Med Assoc Journal* 183: 778-779, 2011.

Bagby RM, **Pollock BG**, McKenzie K, Watson C, Quilty LC: CAMH tests new ground for including cross-cutting dimensional assessment measure in DSM-5. *Canadian Psychiatry Aujourd'hui* 7: 13, 2011.

Reuben DB, Herr KA, Pacala JT, **Pollock BG**, Potter JF, Semla TP et al. *Geriatrics At Your Fingertips*: 13th Edition. New York: The American Geriatrics Society; 2011.

Riddick DS

Mullen Grey AK, **Riddick DS**. The aryl hydrocarbon receptor pathway and the response to 3-methylcholanthrene are altered in the liver of adrenalectomized rats. *Drug Metab. Dispos.* 39: 83-91, 2011.

Salahpour A

Ramsey AJ, Milenkovic M, Oliveira AF, Escobedo-Lozoya Y, Seshadri S, **Salahpour A**, Sawa A, Yasuda R, Caron MG. Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. *Proc Natl Acad Sci U S A.* 5;108(14):5795-800. 2011.

Espinoza S, **Salahpour A**, Masri B, Sotnikova TD, Messa M, Barak LS, Caron MG, Gainetdinov RR. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. *Mol Pharmacol*; 80(3):416-25. 2011.

Salahpour A, Barak LS. Visualizing receptor endocytosis and trafficking. *Methods Mol Biol.*; 756:311-23. 2011.

Schapira M

Santiago C, Nguyen K, **Schapira M**. Druggability of methyl-lysine binding sites. *J Comput Aided Mol Des.*; 25(12):1171-8, 2011.

Artz JD, Wernimont AK, Allali-Hassani A, Zhao Y, Amani M, Lin YH, Senisterra G, Wasney GA, Fedorov O, King O, Roos A, Lunin VV, Qiu W, Finerty P Jr, Hutchinson A, Chau I, von Delft F, MacKenzie F, Lew J, Kozieradzki I, Vedadi M, **Schapira M**, et al. The *Cryptosporidium parvum* kinome. *BMC Genomics.*; 12:478, 2011.

Wallach I, Jaitly N, Nguyen K, **Schapira M**, Lilien R. Normalizing molecular docking rankings using virtually generated decoys. *J Chem Inf Model.*;51:1817-30, 2011.

Campagna-Slater V, Mok MW, Nguyen KT, Feher M, Najmanovich R, **Schapira M**. Structural chemistry of the histone methyltransferases cofactor binding site. *Op cit.*51:612-23, 2011.

Yap DB, Chu J, Berg T, **Schapira M**, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, Aparicio SA. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. *Blood.*; 117(8):2451-9, 2011.

Turgeon Z, Jørgensen R, Visschedyk D, Edwards PR, Legree S, McGregor C, Fieldhouse RJ, Mangroo D, **Schapira M**, Merrill AR. Newly discovered and characterized antivirulence compounds inhibit bacterial mono-ADP-ribosyltransferase toxins. *Antimicrob Agents Chemother.*; 55(3):983-91, 2011.

Artz JD, Wernimont AK, Dunford JE, **Schapira M**, et al. Molecular characterization of a novel geranylgeranyl pyrophosphate synthase from *Plasmodium* parasites. *J Biol Chem.*; 286(5):3315-22, 2011.

Kaustov L, Ouyang H, Amaya M, Lemak A, Nady N, Duan S, Wasney GA, Li Z, Vedadi M, **Schapira M**, Min J, Arrowsmith CH. Recognition and specificity determinants of the human cbx chromodomains. *Op cit.* 286(1):521-9, 2011.

Schimmer BP

Schimmer BP, Tsao J, Cordova M, Mostafavi S, Morris Q, Scheys JO: Contributions of steroidogenic factor 1 to the transcription landscape of Y1 mouse adrenocortical tumor cells. *Mol Cell Endocrinol*; 85-92, 2011.

Parker KL, **Schimmer BP**: Introduction to endocrinology: The hypothalamic-pituitary axis. in: Goodman & Gilman's the Pharmacological Basis of Therapeutics (Brunton LL, Chabner BA, Knollman BC, eds) McGraw-Hill, Inc., New York. 1103-1127, 2011.

Schimmer BP, Funder JW: ACTH; adrenocortical steroids and pharmacology of the adrenal cortex. in: op cit. 1209-1235, 2011

Schimmer BP, Parker KL: Contraception and pharmacotherapy of obstetrical and gynecological disorders. in: op cit. 1833-1852, 2011.

Seeman P

Sromek A, Yu-wei S, Zhang T, George S, **Seeman P**, Neumeyer JL: Synthesis and biological evaluation of N-fluoroalkyl and 2-fluoroalkoxy substituted aporphines: Potential PET ligands for dopamine D2 receptors. *Am. Med. Chem. Soc. Med. Chem. Letts.*, 10: 2(3): 189-194, 2011.

Chen S, **Seeman P**, Liu F: Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's Disease, Huntington's Disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia. *Synapse* 65(2): 119-124, 2011.

Seeman P: All roads to schizophrenia go through dopamine supersensitivity. *Canadian Psychiatry Aujourd'hui*. Winter, p. 11, 2011.

Seeman P: Schizophrenia diagnosis and treatment. *CNS Neuroscience and Therapeutics*. 17(2): 81-82, 2011.

Fubben SJ, Stepanov V, Nakao R, Sromek AW, Zhang TZ, Neumeyer JL, George SR, **Seeman P**, Farde L, Halldin C: The First PET Evaluation of the Fluorine-18 Labeled Dopamine D2/D3 Receptors Agonist, [18F]MCL-524. *Eur. Assoc. Nuclear Med.*, 2011.

Seeman P, Seeman N: Alzheimer's disease: b-amyloid plaque formation in human brain. *Synapse*, 65: 1289-1297 2011.

Seeman N, **Seeman P**, Watanabe M: Psychosis. Discovery of the antipsychotic receptor. Japanese, Tokyo, Seiwa Shoten Publishers, 267, 2011.

Seemle JW

Seemle JW, Italiano Jr JE, Freedman J. Platelets and the immune continuum. *Nature Rev Immunol*;11:264-274, 2011.

Sarpatwari A, Bussel JB, Ahmed M, Erqou1 S, **Semple JW**, et al. Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. *Hematol*; 16:1-6, 2011.

Bredlau A-L, **Semple JW**, Segel G. Management of immune thrombocytopenic purpura in children: potential role of novel agents. *Pediatric Drugs*; 13:1-11, 2011.

Semple JW. Mouse models of ITP; Chapter 1.3. In: *The Handbook: Immune Thrombocytopenia*, 1st Edition (Cines DB, Kuter DJ, Newland AC, Provan D, Semple JW, Eds). European School of Haematology Press, Paris FR, pp 40-54, 2011.

Zimring JC, Lis Welniak L, **Semple JW**, Ness PM, Slichter SJ, Spitalnik SL and the NHLBI Alloimmunization Working Group. Current Problems and Future Directions of Transfusion-Induced Alloimmunization: Summary of an NHLBI Working Group. *Transfusion* 5; 1:435-441, 2011.

Cines DB, Kuter DJ, Newland AC, Provan D, **Semple JW**, Editors. *The handbook: Immune thrombocytopenia*. European School of Haematology Press, Paris FR, 2011.

Shram MJ

Shram MJ, Schoedel KA, Bartlett C, et al. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. *Clin Pharmacol Ther.*; 89(5):683-92, 2011.

Shram MJ, Sellers EM, Romach MK. Oral ketamine as a positive control in human abuse potential studies. *Drug Alcohol Depend*; 114(2-3):185-93, 2011.

Sun HS

Nejatbakhsh N, Guo CH, Lu T, Pei L, Smit A, **Sun HS**, et al. Caltubin promotes neurite elongation and attenuates axonal degeneration by regulating local tubulin levels. *J Neurosci.*, 31(43): 15231-15244, 2011.

Hui K, Arnot M, Shin H-S, **Sun HS**, Feng Z-P. Differential regulation of low and high voltage-activated calcium channels in neonatal rat myocytes following chronic PKA modulation. *Channels*, 5(4): 357-366, 2011.

Tyndale RF

Khokhar JY and **Tyndale RF**. Drug Metabolism within the Brain Changes Drug Response: Selective Manipulation of Brain CYP2B Alters Propofol Effects. *Neuropsychopharmacology*, 36(3): 692-700, 2011.

Cox LS, Faseru B, Mayo MS, Krebill R, Snow TS, Bronars CA, Nollen NL, Choi WS, Okuyemi KS, Salzman GA, Benowitz NL, **Tyndale RF**, Ahluwalia JS. Design, baseline characteristics, and

retention of African American light smokers into a randomized trial involving biological data. *Trials*, 12:22, 1-12, 2011.

Wells S, Flynn A, Graham K, Rehm J, Cairney J, Kates N, Kennedy JL, Lobo DSS, Chaiton M, Menzies P, **Tyndale RF**, Verjee Z. Using a Mobile Laboratory to Study Mental Health, Addictions and Violence: A Research Plan. *Challenges* 2(1), 1-18, 2011.

Strasser AA, Benowitz NL, Pinto A, Tang KZ, Hecht SS, Carmella SG, **Tyndale RF**, Lerman C. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. *Cancer Epidemiology Biomarkers and Prevention* 20(2):234-8, 2011.

Liu T, David SP, **Tyndale RF**, Wang H, Zhou Q, Ding P, He Y-H, Yu X-Q, Chen W, Crump C, Wen X-Z, Chen W-Q. Associations of CYP2A6 genotype with smoking behavior in southern China. *Addiction* 106(5):985-994, 2011.

Falcone M, Jepson C, Benowitz N, Bergen A, Pinto A, Baldwin D, **Tyndale RF**, Lerman C, Ray R. Association of the nicotine metabolite ratio and *CHRNA5/CHRNA3* polymorphisms with smoking rate among treatment-seeking smokers. *Nicotine Tobacco Res* 13:498-503, 2011.

Mwenifumbo JC and **Tyndale RF**. DSM-IV, ICD-10 and FTND: Discordant tobacco dependence diagnoses in adult smokers. *Addiction Research and Therapy*. 2: 1-4, 2011.

Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, **Tyndale RF**. Combined Impact of *CYP2A6* and *CHRNA5-CHRNA3-CHRNA4* Variation on Smoking Behaviors and Lung Cancer Risk. *J Nat Cancer Inst*, 103(17):1342-6, 2011.

Cunningham JA, Leatherdale ST, Selby PL, **Tyndale RF**, Zawertailo L and Kushnir V. Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol. *BMC Public Health*. 28;11:741-751, 2011.

Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, **Tyndale RF**, Flockhart DA. For the Consortium on Breast Cancer Pharmacogenomics (COBRA) CYP2A6 genetic variants, body mass index and age are associated with letrozole plasma concentrations in postmenopausal women with breast cancer. *Clin Pharmacol Therap* 90(5):693-700, 2011.

Roden D and **Tyndale RF**. Pharmacogenomics at the Tipping Point: Challenges and Opportunities. *Op cit*. 89(3):323-7, 2011.

Liu T, Chen W-Q, David SP, **Tyndale RF**, Wang H, Chen Y-M, Yu X-Q, Chen W, Zhou Q, Ling W-H. Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. *Eur J Endocrinology*, 165(6):961-967, 2011.

Ferguson CS, Miksys S, Palmour R, and **Tyndale RF**. Independent and combined effects of ethanol self-administration and nicotine treatment on hepatic CYP2E1 in African Green monkeys. *Drug Metab Disp*, 39(12):2233-41, 2011.

Rehm J, Giesbrecht N, Gliksman L, Graham K, Le AD, Mann , Room R, Rush B, **Tyndale RF**, Wells S. Substance abuse research in a modern health care centre – The case of the Centre for Addiction and Mental Health. *Addiction*, 106(4):689-97, 2011.

Ferguson C and **Tyndale RF**. Cytochrome P450 enzymes in the brain: Emerging evidence for biological significance. *Trends in Pharmacological Sciences*. 32(12):708-14, 2011.

Uetrecht JP

Metushi IG, Cai P, Zhu X, Nakagawa T, **Uetrecht JP**. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. *Clin Pharmacol Ther.*;89(6):911-4, 2011.

Zhu X, Li J, Liu F, **Uetrecht JP**. Involvement of T helper 17 cells in D-penicillamine-induced autoimmune disease in Brown Norway rats. *Toxicol Sci.*; 120(2):331-8, 2011.

Warsh JJ

Manceur AP, Tseng M, Holowacz T, Witterick I, Weksberg R, McCurdy RD, **Warsh JJ**, Audet J. Inhibition of glycogen synthase kinase-3 enhances the differentiation and reduces the proliferation of adult human olfactory epithelium neural precursors. *Exp Cell Res.*; 317(15):2086-98, 2011.

Uemura T, Green M, Corson TW, Perova T, Li PP, **Warsh JJ**. Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder. *Bipolar Disord.*; 13(1):41-51, 2011.

Pinto C, Souza RP, Lioult D, Semeralul M, Kennedy JL, **Warsh JJ**, Wong AH, Luca VD. Parent of origin effect and allelic expression imbalance of the serotonin transporter in bipolar disorder and suicidal behaviour. *Eur Arch Psychiatry Clin Neurosci.*; 261(8):533-8, 2011.

Wells PG

Lee CJ, Shibata N, Wiley MJ, **Wells PG**. Fluorothalidomide: a characterization of maternal and developmental toxicity in rabbits and mice. *Toxicol Sci*; 122(1):157-69, 2011.

Lee CJ, Gonçalves LL, **Wells PG**. Resistance of CD-1 and ogg1 DNA repair-deficient mice to thalidomide and hydrolysis product embryopathies in embryo culture. *Op cit.* 122:146-56, 2011.

Lee CJ, Gonçalves LL, **Wells PG**. Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism. *FASEB J.*; 25(7):2468-83, 2011.

Abramov JP, **Wells PG**. Embryonic catalase protects against endogenous and phenytoin-enhanced DNA oxidation and embryopathies in acatalasemic and human catalase-expressing mice. *Op cit.* 25(7):2188-200, 2011.

Miller L, **Wells PG**. Altered methanol embryopathies in embryo culture with mutant catalase-deficient mice and transgenic mice expressing human catalase. *Toxicol Appl Pharmacol.*; 252(1):55-61, 2011.

Abramov JP, **Wells PG**. Embryoprotective role of endogenous catalase in acatalasemic and human catalase-expressing mouse embryos exposed in culture to developmental and phenytoin-enhanced oxidative stress. *Toxicol Sci*; 120:428-38, 2011.

Ramkissoon A, **Wells PG**. Human prostaglandin H synthase (hPHS)-1 and hPHS-2 in amphetamine analog bioactivation, DNA oxidation, and cytotoxicity. *Op cit*.120:154-62, 2011.

McCallum GP, Siu M, Ondovcik SL, Sweeting JN, **Wells PG**. Methanol exposure does not lead to accumulation of oxidative DNA damage in bone marrow and spleen of mice, rabbits or primates. *Mol Carcinog*.; 50(3):163-72, 2011.

Jeng W, Ramkissoon A, **Wells PG**. Reduced DNA oxidation in aged prostaglandin H synthase-1 knockout mice. *Free Radic Biol Med.*; 50(4):550-6, 2011.

Ramkissoon A, **Wells PG**. Human prostaglandin H synthase (hPHS)-1- and hPHS-2-dependent bioactivation, oxidative macromolecular damage, and cytotoxicity of dopamine, its precursor, and its metabolites. *Op cit*. 50(2):295-304,2011.

Sweeting JN, Siu M, Wiley MJ, **Wells PG**. Species- and strain-dependent teratogenicity of methanol in rabbits and mice. *Reprod Toxicol*. 2011 Jan;31(1):50-8. Epub 2010 Oct 16. PubMed PMID: 20955785.

McCallum GP, Siu M, Sweeting JN, **Wells PG**. Methanol exposure does not produce oxidatively damaged DNA in lung, liver or kidney of adult mice, rabbits or primates. *Toxicol Appl Pharmacol.*; 250(2):147-53, 2011.

McCallum GP, Wong AW, **Wells PG**. Cockayne syndrome B protects against methamphetamine-enhanced oxidative DNA damage in murine fetal brain and postnatal neurodevelopmental deficits. *Antioxid Redox Signal.*; 14(5):747-56, 2011.

Wong ACH

Pinto C, Souza RP, Lioult D, Semeralul M, Kennedy JL, Warsh JJ, **Wong AH**, De Luca V. Parent of origin effect and allelic expression imbalance of the serotonin transporter gene in bipolar disorder and suicidal behavior. *Eur Arch of Psychiatry and Neuroscience*; 261(8):533-8, 2011.

Lee FH, Kaidanovich-Beilin O, Roder JC, Woodgett JR, **Wong AH**: Genetic inactivation of GSK3 α rescues spine deficits in Disc1-L100P mutant mice, *Schizophrenia Res* 129 74-76 2011.

Lee FH, Fadel MP, Preston-Maher K, Cordes SP, Clapcote SJ, Price DJ, Roder JC, **Wong AH**: Disc1point mutations in mice alter development of the cerebral cortex. *J Neuroscience* 2, 31(9):3197-3206, 2011.

Taber KH, Salpekar J, **Wong AH**, Hurley RA: Developmental origins for neuropsychiatric illness. *J Neuropsychiatry Clinical Neurosciences* ;23 (1):1-5, 2011.

Souza RP, Rosa DVF, Romano-Silva MA, Zhen M, Meltzer HY, Lieberman JA, Remington G, Kennedy JL, **Wong AH**: Lack of association of NALCN genetic variants with schizophrenia. *Psychiatry Research*, 28;185(3):450-2, 2011.

De Luca V, Souza RP, Zai CC, Panariello F, Javaid N, Strauss J, Kennedy JL, Tallerico T, **Wong AH**: Parent of origin effect and differential allelic expression of BDNF Val66Met in suicidal behaviour. *World J Biol Psychiatry*; 12(1):42-7, 2011.

Young LT

Gawryluk JW, Wang JF, Andreazza AC, Shao L, **Young LT**. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. *Int J Neuropsychopharmacology*. 14(1):123-30, 2011

Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, **Young LT**. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. *Op cit*. 14(8):1069-74, 2011.

Young LT, Yatham LN, Andreazza AC, Nery FG, Grinberg LT, Heinsen H, Lafer B. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoptosis. *Op cit*. 14(8):1075-89, 2011.

Tan H, **Young LT**, Shao L, et al. Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. *Op cit*. 23:1-11, 2011.

Kandratavicius L, Hallak JE, **Young LT**, Assirati JA, Carlotti CG Jr, Leite JP. Differential Aberrant sprouting in temporal lobe epilepsy with psychiatric co-morbidities. *Psychiatry Res*. 2011 July 7.

Blumberger DM, Mulsant BH, Fitzgerald PB, Rajii TK, Ravindran AV, **Young LT**, Levinson AJ, Daskalakis ZJ. A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression. *World J Biol Psychiatry*, 2011 July 8.

Gigante AD, Andreazza AC, Lafer B, Yatham LN, Beasley CL, **Young LT**. Decreased mRNA expression of uncoupling protein 2, a mitochondrial proton transporter, in post-mortem prefrontal cortex from patients with bipolar disorder and schizophrenia. *NeurosciLett.*; 505:47-51, 2011.

Kupfer DJ, Angst J, Berk M, Dickerson F, Frangou S, Frank E, Goldstein BI, Harvey A, Laghrissi-Thode F, Leboyer M, Ostacher MJ, Sibille E, Strakowski SM, Suppes T, Tohen M, Yolken RH, **Young LT**, Zarate CA. Advances in bipolar disorder: selected sessions from the 2011 International Conference on Bipolar Disorder. *Ann N Y Acad Sci*; 1242(1):1-25, 2011.

Zack M

Steinberg L., Tremblay AM, **Zack M.**, et al. Effects of stress and alcohol cues in men with and without gambling and alcohol use disorders. *Drug and Alcohol Dependence*, 119: 46-55. doi:10.1016/j.drugalcdep, 2011.

Zack M. What can we learn from the pervasive linkage of impulsivity and addictive behavior? *Frontiers in Psychiatry*, 1, 139, 2011.

Zack M., Woodford, TM, Tremblay AM, et al. Stress and alcohol cues exert conjoint effects on go and stop signal responding in male problem drinkers. *Neuropsychopharmacol.* 36, 445-458, 2011.

Zawertailo L

Cunningham JA, Leatherdale ST, Selby PL, Tyndale RF, **Zawertailo L,** Kushnir V. Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol. *BMC Public Health.*; 11:741, 2011.

Lobo DS, **Zawertailo L,** Selby P, Kennedy JL. The role of ANKK1 and TTC12 genes on drinking behaviour in tobacco dependent subjects. *World J Biol Psychiatry.*; 13(3):232-8, 2011.

Bacher I, Houle S, Xu X, **Zawertailo L,** et al. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. *Arch Gen Psychiatry.*; 68(8):817-26, 2011.

Steinberg L, Tremblay AM, Zack M, Busto UE, **Zawertailo LA.** Effects of stress and alcohol cues in men with and without problem gambling and alcohol use disorder. *Drug Alcohol Depend.*; 119(1-2):46-55, 2011.

Costello MJ, Sproule B, Victor JC, Leatherdale ST, **Zawertailo L,** Selby P. Effectiveness of pharmacist counseling combined with nicotine replacement therapy: a pragmatic randomized trial with 6,987 smokers. *Cancer Causes Control.*; 22(2):167-80, 2011.

Ph.D. Theses (2011)

Ho, Manki (2011). Impact of CYP2A6 Genetic Variation on Nicotine Metabolism and Smoking Behaviors in Light Smoking Populations of Black African Descent. Supervisor: Dr. R.F. Tyndale.

Mann, Amandeep (2011). Brain CYP2D6 and Its Role in Neuroprotection Against Parkinson's Disease. Supervisor: Dr. R.F. Tyndale.

Mistry, Helena (2011). UHRF1 and the DNA Damage Response. Supervisor: Dr. J. Peter McPherson.

Mullen Grey, Anne (2011). Adrenalectomy and Glucocorticoid Effects on the Rat Hepatic Aryl Hydrocarbon Receptor Pathway and the Response to Aromatic Hydrocarbons. Supervisor: Dr. D.S. Riddick.

Verma, Vaneeta (2011). Regulation of the Dopamine D1-D2 Receptor Heterooligomer. Supervisor(s): Dr. Brian F. O'Dowd and Dr. Susan R. George.

M.Sc. Theses (2011)

Barbuto, Richard (2011). "Characterizing Developmental Consequences of NMDA Receptor Hypofunction". Supervisor: Dr. J. Mitchell.

Binnington, Matthew (2011). CYP2A6 and CYP2B6 Genetic Variation, and Tobacco Use Behaviors and Biomarkers in Alaska Natives. Supervisor: Dr. R.F. Tyndale.

Francis, Philip (2011). Neuroanatomical Correlates of Depressive Symptoms Following Acute Ischemic Stroke. Supervisor: Dr. K. Lanctôt & Dr. D.M. Grant.

Gulersen, Moti (2011). Characterization of NP22 and its Potential Role in NMDA Receptor-Mediated Transmission. Supervisor(s): Dr. Amy Ramsey & Dr. Susan R. George.

Isabella, Silvia (2011). Chronic Deep Brain Stimulation and Pharmacotherapy for the Treatment of Depression: Effect on Neuroplasticity in Rats. Supervisor: Dr. J. Nobrega.

Kalia, Aditi (2011). Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling Reinforcement in Pathological Gamblers and Healthy Controls. Supervisor: Dr. Martin Zack.

Kwong, Wilson Wing-Jun (2011). Effect of Selective/Non-Selective COX Inhibition on Rosuvastatin-Mediated Protection from Ischemia-Perfusion Induced Endothelial Dysfunction in the Human Forearm Vasculature. Supervisor: Dr. J.D. Parker.

Lee, Han Youl (2011). Insight into the Cargo Recognition Mechanism of Kinesin Light Chain 1. Supervisor(s): Dr. H-W. Park and Dr. J.M. Mitchell.

Milenkovic, Marija (2011) Characterizing Developmental Consequences of NMDA Receptor Hypofunction. Supervisor(s): Dr. A. Ramsey & Dr. D.M. Grant.

Powis, Melanie (2011). Modulation of Aryl Hydrocarbon Receptor-Dependent Transcription by Halogenated Compounds and Pharmaceuticals. Dr. J. Matthews.

Saleem, Mahwesh (2011). Comparing Memory and Executive Function Performance in Coronary Artery Disease Patients Dichotomized into Low and High Cortisol Groups Over One Year of Cardiac Rehabilitation. Supervisor: Dr. K. Lanctôt.

Stern, Seth (2011). Comparison of Folic Acid Pharmacokinetics in Obese and Non-obese Women of Childbearing Age: Implications for Periconceptional Folic Acid Dosing. Supervisor: Dr. G. Koren.

Trepanier, Marco (2011). Anticonvulsant Effects of Docosahexaenoic Acid in Rodents. Supervisor: Dr. W.M. Burnham.